Semaglutide Titration: Why Dose Escalation Is Slow
Semaglutide is escalated slowly — typically starting at 0.25mg weekly and increasing every four weeks — to reduce gastrointestinal side effects. Rushing the schedule increases nausea and dropout without improving results. Rushing the schedule increases nausea and dropout without improving results; individual pace varies, and significant side effects at a dose step usually mean holding at the current dose longer rather than pushing forward.
- Standard escalation starts at 0.25mg weekly, rising every ~4 weeks.
- Slow titration reduces nausea and GI side effects.
- The maintenance dose for weight management is 2.4mg weekly.
- Rushing titration increases side effects without better outcomes.
The standard schedule
For weight management, semaglutide (Wegovy) follows a defined escalation: 0.25mg weekly for four weeks, then 0.5mg, then 1mg, then 1.7mg, reaching the 2.4mg maintenance dose over about 16-20 weeks. Each step lasts roughly four weeks.
This gradual increase is deliberate. Starting at a low dose and stepping up slowly gives the body time to adapt to the medication's effects on the gut.
The diabetes products (Ozempic) use a similar principle with somewhat different target doses.
Why slow titration matters
The main reason for slow escalation is tolerability. GLP-1 medications commonly cause nausea, and less often vomiting, diarrhea, or constipation, especially when starting or increasing the dose. A gradual increase substantially reduces the severity of these effects.
Rushing the schedule — jumping to a high dose quickly — increases the likelihood of significant nausea and is a common reason people stop treatment. It does not produce faster or better weight loss.
The escalation schedule is therefore about keeping people on the medication long enough to benefit, not about caution for its own sake.
| Weeks | Weekly dose |
|---|---|
| 1-4 | 0.25mg |
| 5-8 | 0.5mg |
| 9-12 | 1mg |
| 13-16 | 1.7mg |
| 17+ | 2.4mg (maintenance) |
Titration and compounded products
Compounded semaglutide may not follow the same standardized dosing as the approved product, and dose accuracy depends on the compounding pharmacy. This is one of the practical risks of compounded formulations: the titration you receive may differ from the studied schedule.
Some compounded programs offer non-standard dosing or microdosing that has no basis in the trial evidence. The approved titration schedule exists because it was studied; deviations have not been.
If you are on a compounded product, your titration should still be directed by your clinician, following approved-product principles as closely as the formulation allows.
Individual variation
Not everyone tolerates the standard schedule at the same pace. Some people need to stay longer at a given dose before increasing; others tolerate escalation well. The schedule is a default, not a mandate.
If side effects are significant at a dose increase, the appropriate response is often to hold at the current dose longer rather than push forward. This is a clinical judgment.
Communicate side effects to your clinician so the schedule can be adjusted to you.
| Faster escalation | Result |
|---|---|
| Jump to high dose | More nausea, more dropout |
| Standard schedule | Better tolerability, same efficacy |
The bottom line
Semaglutide is titrated slowly — starting at 0.25mg and rising every four weeks to a 2.4mg maintenance dose — specifically to reduce gastrointestinal side effects and keep people on treatment.
Rushing the schedule increases nausea and dropout without improving results. Individual pace varies, and side effects should guide adjustments.
This is educational information; your titration should be directed by your clinician.
Frequently asked questions
Why is semaglutide started at a low dose?
To reduce gastrointestinal side effects like nausea. A gradual increase lets the body adapt and keeps people on treatment.
What is the maintenance dose?
For weight management, 2.4mg weekly, reached over about 16-20 weeks of escalation.
Can I escalate faster to lose weight quicker?
No. Faster escalation increases side effects without improving results, and often causes people to stop treatment.
Does compounded semaglutide follow the same schedule?
Not necessarily. Dose accuracy depends on the pharmacy, and some programs use non-standard dosing without trial support. Titration should still be clinician-directed.
Sources
- FDA — drug labels and compounding status (Drugs@FDA, fda.gov/drugs/human-drug-compounding).
- NEJM — STEP, SELECT, SURMOUNT, SURPASS, SUSTAIN, PIONEER, FLOW trial publications.
- ClinicalTrials.gov registrations and prescribing information.
- Evidence policy and ledger: evidence policy.